SART1

Across TCGA pan-cancer cohorts, SART1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SART1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SART1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SART1 is over-expressed in tumor.

HNSC, LIHC, and COAD are the cancer types where SART1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SART1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.088	<.001	12	view →
LIHC	Female	II,III,IV	+1.242	<.001	9	view →
COAD	All	All	+0.418	<.001	9	view →
KIRC	All	III,IV	+0.326	<.001	9	view →
STAD	Male	II,III,IV	+0.991	<.001	7	view →
CHOL	All	All	+1.617	<.001	5	view →
ESCA	All	All	+0.820	<.001	5	view →
LUSC	Male	II,III,IV	+0.743	<.001	5	view →
KIRP	All	IV	+0.747	.026	2	view →
BLCA	All	All	+0.379	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SART1–HNSC

Open the HNSC breakdown →